GlassScriptPhysician profile
Michael Ramos Lao
NPI 1902920119
$7,160.82
in general payments reported to CMS, 2019-2025
29 companies · $744 in 2025
The $744 reported for 2025 was more than what 88% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $566 · 2020: $370 · 2021: $3,834 · 2022: $440 · 2023: $821 · 2024: $385 · 2025: $744.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,757 · Education: $193.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,757.40 |
| Education | $193.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,545.30 | 2020-2024 | |
| Abbvie INC. | $504.29 | 2019-2025 | |
| Astellas Pharma US INC | $441.37 | 2023-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $441.27 | 2019-2024 | |
| Sage Therapeutics, LLC | $285.58 | 2024-2025 | Zurzuvae |
| Pacira Pharmaceuticals Incorporated | $260.81 | 2019-2025 | Exparel |
| Mayne Pharma Commercial LLC | $197.98 | 2021-2022 | |
| Organon LLC | $182.58 | 2021-2024 | Nexplanon |
| Exeltis, USA INC. | $169.93 | 2021-2025 | Slynd, Tyblume |
| Ethicon US, LLC | $121.75 | 2021-2025 | Vistaseal, Stratafix |
| Biogen, INC. | $119.78 | 2025 | Zurzuvae |
| Myovant Sciences INC. | $114.27 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $104.02 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $101.43 | 2019-2021 | |
| Avion Pharmaceuticals | $94.65 | 2019-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $83.31 | 2019 | |
| Hologic Sales and Service, LLC | $63.24 | 2023-2024 | Thinprep 2000 Processor, Aptima, Coolseal Generator |
| Smith+Nephew, INC. | $50.61 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $45.50 | 2023-2024 | Myfembree |
| Amag Pharmaceuticals, INC. | $38.81 | 2019 | |
| Agile Therapeutics, INC. | $37.25 | 2021-2022 | |
| Allergan, INC. | $32.14 | 2019-2020 | |
| Boston Scientific Corporation | $31.17 | 2019 | |
| Aimmune Therapeutics, INC. | $21.55 | 2025 | Zenpep |
| Supernus Pharmaceuticals, INC. | $18.01 | 2025 | Qelbree |
| Assertio Therapeutics, INC. | $15.20 | 2019 | |
| Evofem Biosciences, INC. | $13.49 | 2021 | |
| Therapeuticsmd, INC. | $13.38 | 2021 | |
| Acessa Health INC. | $12.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Lao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.